BACKGROUND:Nicotine deprivation symptoms, including fatigue and attentional deficits, predict relapse following smoking cessation. Modafinil (Provigil), a wakefulness medication shown to have efficacy for the treatment of cocaine addiction, was tested as a novel therapy for nicotine dependence in a double-blind placebo-controlled trial. METHODS:One hundred and fifty-seven treatment-seeking smokers received brief smoking cessation counseling and were randomized to: (1) 8 weeks of modafinil (200mg/day), or (2) 8 weeks of placebo. The primary outcome was biochemically verified 7-day point prevalence abstinence at the end of treatment (EOT). Secondary outcomes included cigarette smoking rate and post-quit nicotine deprivation symptoms (e.g., negative affect, withdrawal). RESULTS: In this interim study analysis, EOT quit rates did not differ between treatment arms (42% for placebo vs. 34% for modafinil; OR=0.67 [0.34-1.31], p=0.24). Further, from the target quit date to EOT, the daily smoking rate was 44% higher among non-abstainers in the modafinil arm, compared to non-abstainers in the placebo arm (IRR=1.44, CI95=1.09-1.89, p<0.01). Modafinil-treated participants also reported greater increases in negative affect and withdrawal symptoms, vs. participants randomized to placebo (ps<0.05). CONCLUSIONS: These data do not support the use of modafinil for the treatment of nicotine dependence and, as a consequence, this trial was discontinued. Cigarette smoking should be considered when modafinil is prescribed, particularly among those with psychiatric conditions that have high comorbidity with nicotine dependence.
RCT Entities:
BACKGROUND:Nicotine deprivation symptoms, including fatigue and attentional deficits, predict relapse following smoking cessation. Modafinil (Provigil), a wakefulness medication shown to have efficacy for the treatment of cocaine addiction, was tested as a novel therapy for nicotine dependence in a double-blind placebo-controlled trial. METHODS: One hundred and fifty-seven treatment-seeking smokers received brief smoking cessation counseling and were randomized to: (1) 8 weeks of modafinil (200mg/day), or (2) 8 weeks of placebo. The primary outcome was biochemically verified 7-day point prevalence abstinence at the end of treatment (EOT). Secondary outcomes included cigarette smoking rate and post-quit nicotine deprivation symptoms (e.g., negative affect, withdrawal). RESULTS: In this interim study analysis, EOT quit rates did not differ between treatment arms (42% for placebo vs. 34% for modafinil; OR=0.67 [0.34-1.31], p=0.24). Further, from the target quit date to EOT, the daily smoking rate was 44% higher among non-abstainers in the modafinil arm, compared to non-abstainers in the placebo arm (IRR=1.44, CI95=1.09-1.89, p<0.01). Modafinil-treated participants also reported greater increases in negative affect and withdrawal symptoms, vs. participants randomized to placebo (ps<0.05). CONCLUSIONS: These data do not support the use of modafinil for the treatment of nicotine dependence and, as a consequence, this trial was discontinued. Cigarette smoking should be considered when modafinil is prescribed, particularly among those with psychiatric conditions that have high comorbidity with nicotine dependence.
Authors: Danielle C Turner; Trevor W Robbins; Luke Clark; Adam R Aron; Jonathan Dowson; Barbara J Sahakian Journal: Psychopharmacology (Berl) Date: 2002-11-01 Impact factor: 4.530
Authors: Douglas E Jorenby; J Taylor Hays; Nancy A Rigotti; Salomon Azoulay; Eric J Watsky; Kathryn E Williams; Clare B Billing; Jason Gong; Karen R Reeves Journal: JAMA Date: 2006-07-05 Impact factor: 56.272
Authors: John R Hughes; Josue P Keely; Ray S Niaura; Deborah J Ossip-Klein; Robyn L Richmond; Gary E Swan Journal: Nicotine Tob Res Date: 2003-02 Impact factor: 4.244
Authors: Kenneth A Perkins; K N Roy Chengappa; Joshua L Karelitz; Margaret C Boldry; Valerie Michael; Taylor Herb; Jessica Gannon; Jaspreet Brar; Lisa Ford; Stefanie Rassnick; Darlene H Brunzell Journal: Neuropsychopharmacology Date: 2017-11-29 Impact factor: 7.853
Authors: Catherine Anne Martin; Joshua Lile; Greg Guenthner; Joye C Anestis; Seth R Batten; Thomas H Kelly Journal: J Clin Psychopharmacol Date: 2014-04 Impact factor: 3.153
Authors: Kenneth A Perkins; Joshua L Karelitz; Valerie C Michael; Margaret Fromuth; Cynthia A Conklin; K N Roy Chengappa; Chris Hope; Caryn Lerman Journal: Nicotine Tob Res Date: 2015-04-20 Impact factor: 4.244
Authors: Andrea H Weinberger; Erin L Reutenauer; Peter I Jatlow; Stephanie S O'Malley; Marc N Potenza; Tony P George Journal: Drug Alcohol Depend Date: 2009-11-24 Impact factor: 4.492
Authors: Kenneth A Perkins; Caryn Lerman; Joshua L Karelitz; Nancy C Jao; K N Roy Chengappa; Garrett M Sparks Journal: Addiction Date: 2013-07-12 Impact factor: 6.526
Authors: M D Scofield; J A Heinsbroek; C D Gipson; Y M Kupchik; S Spencer; A C W Smith; D Roberts-Wolfe; P W Kalivas Journal: Pharmacol Rev Date: 2016-07 Impact factor: 25.468